# NEONIPIGA: HCP commentary report

> 68 HCP sources screened · 1222 verified claims from 61 sources · 12 findings. Updated 2026-10-08.

## Report

- Trial: Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
- NCT ID: NCT04006262
- Registry: https://clinicaltrials.gov/study/NCT04006262
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Phase: Phase 2
- Status: Active not recruiting
- Drugs: nivolumab, ipilimumab
- Indications: Gastroesophageal adenocarcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-08
- Last checked: 2026-10-08
- Release hash: 791593395914ae13f346c571216464187f6abd57d1363682872c5c3f69c36118

## Counts

- HCP commentary sources screened: 68
- Sources cited by verified claims: 61
- Verified claims: 1,222
- Findings: 12
- People found in screened sources: 91
- People identity-verified: 66
- Voices cited: 72

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

NEONIPIGA prompts a practical question: can immunotherapy replace chemotherapy before surgery for resectable stomach or gastroesophageal-junction cancer with deficient mismatch repair or high microsatellite instability? Clinicians discuss response-selected surgery avoidance, dual versus single-agent immunotherapy, toxicity, response and survival endpoints, postoperative treatment, biomarker confirmation, staging, radiation alternatives and PD-L1 selection for chemotherapy-plus-immunotherapy regimens. Other topics include treatment duration, reimbursement, surveillance, circulating tumor DNA, patient support and access to follow-up.

## Open Medical Affairs question

What response definition, surveillance and salvage safeguards would address the concern about withholding a needed curative operation?

## Findings (titles)

- F1. Organ preservation is compelling for selected responders, but clinical response does not settle the need for surgery
- F2. Immunotherapy incorporation attracts support; chemotherapy omission and the preferred combination remain contested
- F3. Dual blockade's response appeal is limited by immune toxicity, while monotherapy remains a disputed alternative
  - Context for these views, not raised in the commentary cited above. The trial publication reports: Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred).
- F4. High pCR is persuasive biological activity, not a demonstrated comparative survival advantage
- F5. After resection, clinicians separate perioperative immunotherapy from an unresolved adjuvant-only decision
- F6. Early tumor-specific testing and confirmation—not presumed MSI or a single positive biopsy—shape treatment choices
- F7. Surgery alone remains a conditional choice when downstaging is unnecessary or immediate local control matters
- F8. Funding and approval boundaries alter treatment delivered, even when clinicians favor immunotherapy
- F9. Radiation's role is disputed, with systemic-control arguments and selective exceptions kept distinct
- F10. For chemotherapy-plus-immunotherapy alternatives, PD-L1-negative disease prompts genuine disagreement about withholding treatment
- F11. Treatment duration and intensity are negotiated around response, postoperative recovery and tolerability
- F12. Organ preservation requires a surveillance-and-salvage system; ctDNA and patient support do not remove its limits

## Sample findings

### F1. Organ preservation is compelling for selected responders, but clinical response does not settle the need for surgery

An X-thread author asked how to specify a complete clinical response and plan surveillance for a possible watch-and-wait pathway in dMMR gastric or gastroesophageal-junction cancer.

Source: X thread, 2022-08-17.

### F12. Organ preservation requires a surveillance-and-salvage system; ctDNA and patient support do not remove its limits

A guest in a YouTube discussion asked who is represented in the evidence and databases supporting circulating tumor DNA and RNA sequencing tests, and whether measurements are comparable across ancestry groups and disease types.

Source: YouTube video, 2026-02-09.

## Trial aspects

| Aspect | Coverage | Claims | Sources |
| --- | --- | ---: | ---: |
| Response-selected surgery avoidance | discussed | 11 | 8 |
| Chemotherapy omission versus chemoimmunotherapy | discussed | 13 | 7 |
| Dual versus single-agent immunotherapy and safety | discussed | 11 | 4 |
| pCR, survival and the threshold for practice change | discussed | 11 | 7 |
| Postoperative immunotherapy, chemotherapy or observation | discussed | 13 | 5 |
| Early MSI/MMR testing, confirmation and tumor heterogeneity | discussed | 17 | 10 |
| Surgery alone, downstaging needs and staging work-up | discussed | 15 | 8 |
| Guidelines, reimbursement and access-dependent treatment | discussed | 14 | 5 |
| Radiation and systemic-treatment alternatives | discussed | 17 | 11 |
| PD-L1 selection for perioperative chemotherapy-plus-immunotherapy | discussed | 14 | 7 |
| Duration, dose adaptation and postoperative treatment burden | discussed | 19 | 7 |
| Surveillance capacity, ctDNA, patient support and equitable implementation | discussed | 26 | 10 |

## Cited sources by channel

- Podcasts: 21
- Publications: 1
- X threads: 25
- YouTube: 14

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice.

- Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
- 1 matching source (1 podcast) could not be read and is not included.
- For 4 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- 16 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
- 2 further source limits are recorded in the machine-readable scope of this record.
- The reviewed commentary comes from 68 retained sources, not 68 independent clinicians. Some recordings appear in more than one publication format, and several posts repeat the same study summary; repetition should not be interpreted as independent agreement.
- Some public discussions could not be reviewed, and searches focused on the trial identifier and indexed trial names. Unnamed references and unusual transcriptions may therefore be absent, limiting claims about the breadth of the conversation.
- Several recordings rely on the available written transcript rather than a separately checked recording. Some passages establish no speaker name, or only a first name; adjacent named comments do not establish who voiced those passages.
- Study names, regimens and numerical descriptions sometimes differ between accounts or remain unclear. They are retained as what the speaker reported, not reconciled into corrected clinical facts. Thomas Samaille's reported pCR figure, for example, differs from the verified publication result.
- Guideline, approval and reimbursement statements describe the speaker's setting and the evidence available during that discussion. They do not establish current global availability, and publication dates are not automatically session or readout dates.
- NEONIPIGA's single-arm phase II context and the surgical pCR denominator limit comparative conclusions. Other-study comparisons and individual experiences do not establish superiority, equivalent efficacy or a survival benefit from omitting chemotherapy or surgery.
- Allan Pereira's posts are attributable to the named author, but his clinical role is explicitly unresolved in the supplied professional context. His interpretations are retained as attributed commentary, not additional verification of clinical practice.
- The report preserves views from different timepoints and clinical settings. Apparent differences between a clinician's comments do not, by themselves, establish a change of mind.

## Offer

- Size: Deep (60 commentary sources cited)
- Current edition: $1,950. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (66 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/neonipiga-nct04006262
- Agents: POST https://www.erudio.com/api/orders with {"report": "neonipiga-nct04006262", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=neonipiga-04006262

## Cite

Erudio Health. NEONIPIGA (NCT04006262): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/neonipiga-nct04006262

## Machine access

- JSON: https://www.erudio.com/reports/neonipiga-nct04006262.json
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "neonipiga-04006262"}`